Psychiatric Digital Biomarkers Market By Data Source (Smartphone-Derived Behavioral Data, Wearable Sensor Data, Voice & Speech Biomarkers, Computerized Cognitive & Attention Assessments, Medication-Adherence & Connected Drug-Device Data); By Application (Clinical-Trial Endpoints & Patient Stratification, Objective ADHD Assessment, Relapse & Crisis Monitoring, Treatment-Response Monitoring, Screening & Triage, Medication-Adherence Monitoring); By End User (Pharmaceutical & Biotechnology Companies, CROs, Hospitals & Specialist Mental-Health Clinics, Academic & Research Institutions, Digital Health & Telehealth Providers, Payers & Insurance Providers); By Psychiatric Indication (ADHD, Depression, Bipolar Disorder, Schizophrenia, Anxiety Disorders, PTSD, Suicide-Risk Monitoring); By Region, Segment Revenue Estimation and Forecast, 2026–2032

Psychiatric Digital Biomarkers Market: Objective Signals Reshape Mental-Health Assessment and Drug Development

The Global Psychiatric Digital Biomarkers Market is projected to grow from USD 755.82 million in 2025 to approximately USD 3.31 billion by 2032, expanding at a robust CAGR of 23.5%, according to Strategic Market Research.

 

Psychiatric care is still guided by brief clinical visits and patient-reported symptoms, even though depression, bipolar disorder, schizophrenia, anxiety, ADHD, and suicide risk can change sharply between appointments. Limited visibility into sleep disruption, mobility decline, cognitive change, social withdrawal, and medication response delays intervention and increases reliance on trial-and-error treatment. Psychiatric digital biomarkers address this gap by converting continuous behavioral and physiological data into objective signals that can support earlier diagnosis, relapse detection, treatment monitoring, and clinical-trial decisions.

 

Psychiatric digital biomarkers track these changes using smartphones, wearables, microphones, motion sensors, computerized tasks, and connected medication systems. Commercial platforms assess mobility, sleep, physical activity, speech, attention, impulsivity, typing patterns, device use, and medication adherence.

 

The sector includes FDA-cleared objective assessments, passive-monitoring platforms, voice-analysis software, wearable endpoints, pharmaceutical trial services, and investigational risk-prediction algorithms. Suppliers generate revenue through completed assessments, software subscriptions, monitored patients, patient-days of sensing, clinical-trial contracts, enterprise licenses, and analytics services.

 

Multimodal Signals Improve Relapse Detection and Trial Decisions

Psychiatric digital biomarkers track changes in sleep, mobility, speech, cognition, and device use between clinical visits. Combining smartphone, wearable, voice, and active assessment data produces stronger relapse and treatment-response signals than single-sensor monitoring.

Pharmaceutical sponsors remain the leading buyers because digital endpoints can reduce site visits, support decentralized trials, improve patient selection, and identify response earlier. Digital-health-technology use in neurological trials grew at an approximately 39% CAGR between 2010 and 2020, supporting wider adoption in psychiatric research. Suppliers with validated algorithms, missing-data controls, and clinician escalation workflows are better positioned than platforms offering stand-alone risk scores.

 

Mental-Health Burden Defines the Addressable Population

Around 1.1 billion people, or nearly one in seven globally, were living with a mental disorder in 2021. Anxiety and depressive disorders accounted for the largest patient groups. In the United States, 59.3 million adults had any mental illness in 2022, equal to 23.1% of the adult population, while approximately 30 million received mental-health treatment.

Disease prevalence overstates the commercial population because eligibility depends on the clinical purpose of each product. Objective ADHD tests target patients already referred for assessment. Relapse platforms focus on diagnosed patients with recurrent episodes. Voice applications are used for screening, triage, monitoring, or pharmaceutical research rather than universal diagnosis.

An estimated 15.5 million U.S. adults had a current ADHD diagnosis in 2023, and approximately half were diagnosed during adulthood. About 7 million children aged 3–17 had received an ADHD diagnosis based on the latest CDC estimates. Diagnostic backlogs, specialist shortages, and complex differential assessment create demand for tools that can add objective evidence without replacing clinical evaluation.

Around 21 million U.S. adults experienced a major depressive episode in 2021, including 14.5 million with severe impairment. Patients with recurrent or treatment-resistant depression represent the most relevant population for continuous sleep, activity, voice, and smartphone monitoring.

The United States recorded 49,316 suicide deaths in 2023, while WHO estimated approximately 727,000 globally in 2021. Digital risk systems remain investigational because no population-level evidence shows that passive monitoring independently reduces suicide mortality. Providers must pair alerts with clinician review, escalation protocols, and defined intervention pathways.

 

Passive Monitoring Supports Recurring Revenue

Smartphones and wearables can collect data over weeks or months without requiring repeated clinical visits. Accelerometers measure movement, geolocation records changes in routine, screen activity indicates disrupted sleep, and wearable sensors track activity and circadian patterns.

Longitudinal collection supports recurring subscriptions, patient-monitoring contracts, data-management fees, and patient-day pricing. Pharmaceutical sponsors can also purchase sensor provisioning, participant support, endpoint analysis, and regulatory documentation as part of clinical-trial contracts.

Active assessments require patients to complete a computerized attention task, cognitive exercise, voice recording, or symptom questionnaire. These measures create a controlled testing environment but depend on patient participation.

Platforms increasingly combine passive and active data. A decline in mobility or sleep regularity may trigger a questionnaire or clinician contact to determine whether the change reflects psychiatric deterioration, physical illness, travel, device non-use, or another cause. Hybrid models can reduce unnecessary alerts and improve interpretation without treating one sensor signal as a diagnosis.

 

ADHD Assessment Establishes the First Regulated Revenue Base

Objective ADHD assessment is the most established commercial use of psychiatric digital biomarkers. QbTest combines a computerized continuous-performance task with motion measurement to quantify inattention, impulsivity, and hyperactivity. QbCheck provides a remotely administered format within a clinician-managed process.

FDA records confirm product-specific 510(k) clearances. NICE recommends QbTest as an option to support ADHD diagnosis in people aged 6–17 when used alongside standard clinical assessment. The recommendation does not support independent diagnosis, and evidence remains insufficient for routine adult use, fully remote diagnosis, and long-term medication monitoring.

The AQUA randomized trial found that 76% of participants whose clinicians received a QbTest report had a diagnostic decision within six months, compared with 50% under standard assessment. Appointment duration decreased by approximately 15%. Providers gain value from faster decisions and shorter consultations rather than from replacing specialist judgment.

NICE’s economic analysis estimated an incremental cost-effectiveness ratio of £6,184 per quality-adjusted life-year for QbTest alongside conventional assessment. The guidance also reported a £69 price for a remote QbCheck assessment, excluding VAT. Per-assessment pricing becomes commercially defensible when objective testing reduces repeat visits or shortens the diagnostic pathway.

Qbtech reported more than one million cumulative test takers by October 2024, over 12,000 healthcare providers, and availability across 44 U.S. states. Current company information also reports availability in 18 countries. The disclosure does not separate unique patients from repeat assessments, but it remains the strongest publicly available utilization indicator in the category.

 

Relapse Models Provide Early Warnings, Not Stand-Alone Decisions

A 2023 study evaluated relapse prediction in 277 patients with major depressive disorder using actigraphy and self-reported symptoms. The 227-patient development cohort produced 73.5% balanced accuracy, 66% sensitivity, 81% specificity, and a 98.3% negative predictive value. An independent 50-patient cohort produced 71% balanced accuracy and a 97.2% negative predictive value.

Positive predictive values remained between 12.5% and 14.6% because relapse events were relatively uncommon. Multiple false alerts may therefore occur for each genuine relapse. Providers must account for clinician review time, patient anxiety, and escalation costs when evaluating these systems.

The strongest use case is earlier identification of patients who may require assessment two to three weeks before a scheduled visit. Relapse models become more valuable when alerts are linked to outreach, symptom confirmation, medication review, or safety planning.

Research in schizophrenia is larger but less standardized. A 2025 review covered 142 studies and 6,294 participants. Variations in devices, populations, outcomes, follow-up periods, and validation methods prevented a single pooled performance claim. Pharmaceutical research and supervised post-discharge monitoring remain more credible applications than autonomous psychosis diagnosis.

 

CNS Trials Monetize Biomarkers Before Routine Reimbursement

Psychiatric drug trials face high placebo response, heterogeneous patient populations, subjective endpoints, and participant attrition. Digital measures can track sleep, activity, cognition, adherence, speech, and daily functioning while participants remain at home.

FDA guidance issued in December 2023 provides a framework for using digital health technologies to collect participant data remotely in medical-product investigations. Sponsors must address device verification, validation, usability, training, cybersecurity, data retention, and missing information. The guidance supports regulatory-grade data collection but does not validate every psychiatric algorithm.

Pharmaceutical companies use digital biomarkers for patient enrichment, dose-response analysis, safety monitoring, decentralized participation, and exploratory endpoint development. Research budgets allow drug developers to purchase these services before health insurers establish routine reimbursement.

Alto Neuroscience applies EEG, neurocognitive assessments, wearable information, and machine learning to identify patient profiles associated with treatment response. Similar precision-psychiatry models can generate revenue through biomarker development, trial enrollment, endpoint analysis, and companion research services.

 

Smartphones Retain the Largest Data-Source Share

Smartphone-derived behavioral data are estimated to account for 36.8% of 2025 revenue under Strategic Market Research’s central-case model. Existing hardware supports mobility, communication, typing, survey, screen-use, and activity measurements without dedicated sensor distribution. Voice biomarkers are projected to record the fastest CAGR of 24.7% from 2026 to 2032. Telehealth platforms, call centers, mobile applications, and connected devices can add voice assessment without requiring patients to wear or purchase separate hardware.

 

Clinical Trials Anchor Application Revenue

Clinical-trial endpoints and patient-stratification services are estimated to hold 34.6% of 2025 revenue. Pharmaceutical sponsors can fund remote data collection, endpoint development, device logistics, and algorithm validation through research budgets. Relapse and crisis monitoring are projected to expand at a 25.3% CAGR through 2032. Adoption will depend on demonstrated reductions in hospitalization, intervention time, or clinical workload rather than the number of alerts generated.

 

Pharmaceutical Buyers Control Procurement

Pharmaceutical companies, biotechnology developers, and CROs are estimated to contribute 41.2% of 2025 revenue. Contracts can include endpoint development, device provisioning, patient onboarding, data-quality management, algorithm validation, and regulatory documentation. Healthcare-provider adoption is projected to grow at a 22.1% CAGR through 2032, led by objective ADHD assessment and supervised relapse monitoring. Hospitals and specialist clinics must still justify integration costs, clinician review time, and responsibility for responding to risk signals.

 

ADHD Leads Indication-Based Revenue

ADHD is estimated to represent 31.4% of 2025 indication-based revenue because it combines cleared objective assessments, defined referral pathways, guideline support, and documented utilization. Depression and bipolar-disorder applications are projected to expand at a combined 24.5% CAGR through 2032. Wearable relapse models, voice analytics, and biomarker-guided drug trials will drive most near-term revenue because mood disorders lack a standardized digital threshold for diagnosis or medication selection.

 

North America Sets the Commercial Benchmark

North America is estimated to hold 44.1% of 2025 revenue, supported by FDA-cleared products, CNS trial activity, enterprise voice companies, and a large diagnosed population. Asia-Pacific is projected to grow at a 24.8% CAGR through 2032 as smartphone delivery reduces hardware requirements. Regional expansion will depend on language-specific validation, local privacy rules, reimbursement, clinical integration, and the effect of cultural differences on speech and behavioral data.

 

Validated Workflows Define Competitive Positioning

Qbtech holds the most established regulated position through FDA-cleared ADHD products, NICE support, more than one million cumulative test takers, and provider distribution across the United States and international markets. A defined clinical decision point and repeatable assessment process support its position more than the volume of data collected.

Sonde Health, Kintsugi, and Canary Speech compete in vocal biomarkers. Sonde provides mental-fitness and cognitive voice analytics and has worked on integration with Qualcomm-powered audio and smart-glasses platforms. Kintsugi uses an API-based model to identify signs associated with depression and anxiety from speech. Canary Speech provides real-time vocal analytics for behavioral-health, clinical-research, and enterprise applications.

Alto Neuroscience applies EEG, cognition, wearables, and treatment-response prediction within proprietary drug-development programs. Otsuka established an earlier drug-device model through Abilify MyCite, which records medication-ingestion events. The approved label did not establish improved adherence or support automatic dose changes.

Healthcare and pharmaceutical buyers increasingly evaluate multilingual performance, demographic validation, data completeness, cybersecurity, integration, regulatory documentation, and escalation procedures alongside algorithm accuracy. Suppliers that connect measurement to a defined clinical or research action can justify higher contract values than vendors selling isolated risk scores.

 

Voice Creates a Low-Hardware Enterprise Channel

Voice platforms can collect data through telephone calls, telehealth appointments, smartphone applications, or connected devices. Sonde describes workflows using approximately 30 seconds of speech, while Kintsugi and Canary market depression- and anxiety-related analytics for clinical and enterprise integration.

Suppliers can charge API fees, per-assessment rates, per-member subscriptions, or enterprise licensing fees. Recording hardware, language, accent, age, respiratory illness, medication, and social environment can affect acoustic features. Buyers therefore require population-specific validation rather than assuming that one voice model will perform consistently across countries and patient groups.

 

Reimbursement Depends on Measurable Decision Impact

Medicare introduced payment mechanisms for qualifying digital mental-health treatment devices and expanded the framework for ADHD-related therapeutic devices. These policies apply to clinician-supervised treatment technologies classified under specified FDA regulations. Passive biomarkers, voice screening, and QbTest do not automatically qualify.

Products that connect measurement to an approved or validated intervention have a stronger payment case than stand-alone dashboards. A stress signal linked to a supervised behavioral intervention may fit an existing treatment pathway, while passive monitoring without a defined clinical response can add cost and liability.

Payers will require evidence of shorter diagnostic pathways, fewer unnecessary consultations, lower hospitalization rates, improved medication management, or reduced clinical-trial costs. Technical accuracy alone does not establish reimbursement value.

 

Privacy and False Alerts Limit Deployment

Psychiatric platforms may process geolocation, sleep patterns, communication behavior, voice recordings, medication use, and signs of emotional deterioration. The FTC amended the Health Breach Notification Rule in 2024 to clarify its application to health applications and connected devices that may operate outside traditional HIPAA-covered systems.

Battery loss, device changes, disabled permissions, non-wear, poor audio, travel, and physical illness can resemble psychiatric deterioration. Speech and behavioral models may also perform differently across languages, age groups, socioeconomic conditions, disabilities, and device types.

False-positive alerts increase clinician workload and can lead to unnecessary outreach or intervention. False-negative results may delay care. Health systems and pharmaceutical sponsors increasingly require missing-data rules, subgroup testing, human review, audit trails, and documented escalation procedures before deployment.

 

Market Outlook

Objective ADHD assessment, CNS clinical trials, enterprise voice licensing, and supervised relapse monitoring will account for most near-term commercial activity. Broad population screening remains less mature because psychiatric conditions do not share a universal digital-biomarker threshold.

ADHD offers the clearest progression from regulatory clearance to guideline support, economic evaluation, and documented utilization. Pharmaceutical research provides the most immediate route for wearable, EEG, speech, and smartphone biomarkers because drug developers can pay for improved participant selection and higher-frequency endpoints without waiting for insurance coverage.

Prospective evidence linking biomarker-triggered action to fewer hospitalizations, faster diagnosis, better treatment allocation, or lower trial failure risk will determine wider adoption. Suppliers that combine validated measurement with data-quality controls, workflow integration, and accountable clinical escalation are better positioned than platforms that only produce proprietary risk scores.

 

Psychiatric Digital Biomarkers Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 755.82 Million
Revenue Forecast in 2032	USD 3.31 Billion
Overall Growth Rate	CAGR of 23.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Data Source, By Application, By End User, By Psychiatric Indication, By Geography
By Data Source	Smartphone-Derived Behavioral Data, Wearable Sensor Data, Voice & Speech Biomarkers, Computerized Cognitive & Attention Assessments, Medication-Adherence & Connected Drug-Device Data
By Application	Clinical-Trial Endpoints & Patient Stratification, Objective ADHD Assessment, Relapse & Crisis Monitoring, Treatment-Response Monitoring, Screening & Triage, Medication-Adherence Monitoring
By End User	Pharmaceutical & Biotechnology Companies, CROs, Hospitals & Specialist Mental-Health Clinics, Academic & Research Institutions, Digital Health & Telehealth Providers, Payers & Insurance Providers
By Psychiatric Indication	ADHD, Depression, Bipolar Disorder, Schizophrenia, Anxiety Disorders, PTSD, Suicide-Risk Monitoring
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Rising demand for objective and continuous mental-health assessment Growing use of digital endpoints in CNS clinical trials Expansion of smartphone, wearable, and voice-based monitoring
Customization Option	Available upon request